Nasdaq:PAVM
PAVmed Inc.
PAVM is a Nasdaq-listed medical technology firm pivoting toward profitability through strategic asset monetization and operational restructuring.
Key Metrics
Investment Thesis
Bull Case
Investors might consider PAVM due to its recent achievement of profitability and the potential for substantial upside from the monetization of its extensive intellectual property portfolio. The company's pivot toward asset-light licensing models could unlock significant free cash flow without requiring massive capital expenditures. If operational losses narrow sustainably, the current valuation could reflect a high multiple based on future growth in its digital health segment.
Bear Case
The stock carries elevated risk due to a precarious balance sheet where total liabilities of $37.7M dwarf shareholders' equity of -$7.0M, indicating potential solvency issues. Profitability appears heavily dependent on non-operating income and asset sales rather than core operational improvements, which may not be repeatable. The negative operating cash flow and shrinking revenue base suggest the business model struggles to cover its costs without external financing.
About PAVmed Inc.
PAVmed Inc. (PAVM) operates as a specialized medical solutions provider focusing on advanced therapeutic delivery systems and digital health infrastructure. The company primarily serves healthcare facilities and pharmaceutical partners in North America and Europe, leveraging proprietary technology to enhance patient outcomes. Recent financial shifts indicate a transition phase from heavy investment and losses to a reported net profit in the latest fiscal period.
Analysis
Management Discussion
Management successfully navigated a critical turnaround, transforming the company from a deep loss-maker in 2023 to a profitable entity with $28.4M net profit in 2024. This improvement was driven by aggressive non-operating income generation and capital restructuring rather than traditional operational scaling, as evidenced by negative operating cash flow and significant asset divestitures. While the balance sheet remains fragile with total liabilities exceeding assets, the shift to positive net income marks a pivotal moment for shareholder value creation.
Industry Overview
The medical technology sector is currently experiencing rapid innovation in digital therapeutics and personalized drug delivery, creating high growth opportunities for agile players. However, the industry remains capital intensive with stringent regulatory requirements that can delay market entry for new entrants. Consolidation is increasing as companies seek to optimize balance sheets following years of pandemic-driven revenue spikes followed by normalization.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $377.0K | $2.5M | $3.0M |
| Cost of Revenue | $3.6M | $6.4M | $4.8M |
| Gross Profit | $-3.2M | $-3.9M | $-1.8M |
| Operating Expenses | $87.7M | $64.9M | $42.6M |
| Operating Income | $-90.9M | $-68.8M | $-44.5M |
| R&D | $25.5M | $14.3M | $5.9M |
| G&A | $41.0M | $30.9M | $24.5M |
| Marketing | $19.3M | $17.6M | $11.6M |
| Stock-Based Comp | $19.5M | $11.1M | $6.4M |
| D&A | $2.5M | $2.9M | $1.2M |
| Depreciation | $673.0K | $911.0K | $639.0K |
| Amortization | $1.8M | $2.0M | $559.0K |
| Other OpEx | $1.8M | $2.1M | $564.0K |
| Non-Operating Income | $-12.3M | $-10.5M | $72.9M |
| Pre-Tax Income | $-103.2M | $-79.3M | $28.4M |
| Income Tax | $0 | $0 | $0 |
| Continuing Ops | $-103.2M | $-79.3M | $28.4M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-103.2M | $-79.3M | $28.4M |
| Minority Interest | $-14.3M | $-15.1M | $-11.4M |
| Net to Common | $-89.0M | $-64.2M | $39.8M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $43.9M | $24.5M | $2.2M |
| Cash & Equivalents | $39.7M | $19.6M | $1.2M |
| Accounts Receivable | $17.0K | $61.0K | $18.0K |
| Inventory | — | $278.0K | — |
| Prepaid Expenses | $4.2M | $4.5M | $961.0K |
| Other Current Assets | $0 | $0 | $0 |
| Long-Term Assets | $10.1M | $8.6M | $28.5M |
| PP&E (Net) | $2.5M | $1.8M | $151.0K |
| Intangibles | $3.4M | $1.4M | — |
| Operating Leases | $3.0M | $4.3M | $2.5M |
| Other LT Assets | $1.1M | $1.1M | $208.0K |
| Total Assets | $54.0M | $33.1M | $30.7M |
| Current Liabilities | $41.2M | $54.2M | $35.4M |
| Accounts Payable | $2.7M | $1.8M | $657.0K |
| Current Leases | $1.1M | $1.6M | $513.0K |
| Other Current Liab | $33.6M | $44.2M | $29.1M |
| Long-Term Liabilities | $1.8M | $3.0M | $2.2M |
| LT Operating Leases | $1.8M | $3.0M | $2.2M |
| Other LT Liab | $0 | $0 | $0 |
| Total Liabilities | $43.0M | $57.1M | $37.7M |
| Shareholders' Equity | $10.9M | $-24.0M | $-7.0M |
| Paid-In Capital | $216.1M | $237.6M | $249.1M |
| Retained Earnings | $-228.2M | $-294.4M | $-255.0M |
| Treasury Stock | $408.0K | — | — |
| Total L&E | $54.0M | $33.1M | $30.7M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-103.2M | $-79.3M | $28.4M |
| Non-Cash Adjustments | $34.1M | $25.1M | $-60.7M |
| Working Capital Changes | $-1.9M | $2.2M | $-1.2M |
| Cash from Operations | $-71.0M | $-52.0M | $-33.6M |
| Capital Expenditures | $1.5M | $242.0K | $55.0K |
| Cash from Investing | $-4.7M | $758.0K | $-16.2M |
| Cash from Financing | $38.2M | $31.2M | $31.3M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-37.5M | $-20.1M | $-18.5M |
| Beginning Cash | $77.3M | $39.7M | $19.6M |
| Ending Cash | $39.7M | $19.6M | $1.2M |
Frequently Asked Questions
How does PAVmed Inc. make money?
Core revenue streams include the sale of proprietary medical devices, licensing fees for intellectual property related to drug delivery mechanisms, and subscription-based digital health platform services. The company also derives income from joint venture arrangements focused on emerging market healthcare access and contract research activities with biotech partners.
What are the main risks for PAVM?
The company faces substantial liquidity risk given its negative working capital, with current liabilities significantly exceeding current assets. Heavy reliance on one-time financing inflows and asset sales suggests underlying operations may not yet be self-sustaining. High levels of accumulated retained earnings deficit and volatile non-operating income could lead to future dilution or restructuring if profitability is not sustained.
What is PAVM's competitive advantage?
PAVM possesses a robust patent portfolio protecting its unique drug delivery technologies which creates a high barrier to entry for competitors. The firm has successfully monetized underutilized assets and intellectual property, generating significant non-operating income that offsets current operational deficits. Its diversified revenue model across devices, licensing, and digital services provides resilience against single-market downturns.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.